Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat (CB-839) in advanced solid tumors
NCT02071862Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Feb 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of telaglenastat in solid tumor, triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 3 more (6 arms), sponsored by Calithera Biosciences. Primary endpoint: Incidence of adverse events. Started Feb 2014; status: completed.
02
Drugs
telaglenastat
03
Conditions
solid tumortriple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)mesothelioma
Beyond the preview
Go deeper on NCT02071862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071862.